Education
About Us
Working with TipRanks
Follow Us
Saniona AB (SE:SANION)
:SANION
SANION Stock Chart & Stats
kr21.10
-kr0.15(-2.06%)
At close: 4:00 PM EST
kr21.10
-kr0.15(-2.06%)
Day’s Range― - ―
52-Week Rangekr5.41 - kr28.30
Previous CloseN/A
Volume191.43K
Average Volume (3M)1.06M
Market Cap
kr2.26B
Enterprise Valuekr1.61B
Total Cash (Recent Filing)kr580.82M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)9.6
Beta-0.35
Next Earnings
May 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding138,030,140
10 Day Avg. Volume913,988
30 Day Avg. Volume1,064,614
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)4.30
Price to Sales (P/S)6.29
P/FCF Ratio13.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr11.00M
Bulls Say, Bears Say
Bulls Say
Improved Cash GenerationThe firm delivered positive operating and free cash flow in 2024–2025 after years of burn, which materially improves sustainability. Durable cash generation reduces near-term financing dependency, supports R&D pacing and partnering negotiation leverage, and underpins multi‑quarter operational stability.
Debt‑Free Balance SheetReporting zero total debt in 2025 materially lowers financial risk and interest burden, giving management flexibility to fund trials or structure partnerships. A conservative leverage profile supports long‑term resilience through R&D cycles and reduces the likelihood of distressed financings during development ramps.
Partnering‑Driven Model & Niche FocusA partnering/licensing model with focus on ion‑channel small molecules lets the company de‑risk commercialization, monetize milestones and royalties, and conserve capital. The specialized ion‑channel expertise creates a durable technical differentiation that supports repeated collaboration opportunities with larger biopharma players.
Bears Say
Revenue VolatilityMaterial swings in revenue across consecutive years indicate heavy reliance on lumpy milestone or licensing receipts. That uneven top‑line makes margins and cash generation difficult to predict, complicates multi‑quarter planning and raises the chance that profitability proves transitory without repeatable revenue streams.
Sharp FCF Decline In 2025Although FCF turned positive overall, a 64.8% decline in a single year shows cash generation is sensitive to timing of partner payments and operating variability. This lumpy pattern can force more frequent external financings or delayed programs, undermining the apparent improvement in cash durability.
Small Scale OperationsA very small headcount constrains internal development bandwidth and increases dependence on external partners and CROs for trial execution. Limited scale raises execution risk for advancing multiple programs concurrently and can slow timelines, making long‑term pipeline delivery more contingent on partner support.
Saniona AB News
SANION FAQ
What was Saniona AB’s price range in the past 12 months?
Saniona AB lowest stock price was kr5.41 and its highest was kr28.30 in the past 12 months.
What is Saniona AB’s market cap?
Saniona AB’s market cap is kr2.26B.
When is Saniona AB’s upcoming earnings report date?
Saniona AB’s upcoming earnings report date is May 27, 2026 which is in 71 days.
How were Saniona AB’s earnings last quarter?
Saniona AB released its earnings results on Feb 26, 2026. The company reported -kr0.302 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.302.
Is Saniona AB overvalued?
According to Wall Street analysts Saniona AB’s price is currently Overvalued.
Does Saniona AB pay dividends?
Saniona AB does not currently pay dividends.
What is Saniona AB’s EPS estimate?
Saniona AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Saniona AB have?
Saniona AB has 138,030,140 shares outstanding.
What happened to Saniona AB’s price movement after its last earnings report?
Saniona AB reported an EPS of -kr0.302 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -14.498%.
Which hedge fund is a major shareholder of Saniona AB?
Currently, no hedge funds are holding shares in SE:SANION
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Saniona AB
Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark. The company's products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity. It also develops SAN711, which is in Phase 1 clinical stage for rare neuropathic disorders; SAN903 that is in preclinical stage for rare inflammatory, fibrotic, and hematological disorders. The company has research and collaboration agreements with Boehringer Ingelheim International GmbH; license agreement with Productos Medix, S.A. de C.V.; research services agreement and a collaboration agreement with Cephagenix ApS. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.
Technical Analysis
Oncopeptides AB
―
SynAct Pharma AB
―
Xbrane Biopharma AB
―
Xspray Pharma AB
―
Cantargia AB
―